Skip to main content

BeOne Medicines Ltd.

BEIGF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001651308

In the last 90 days, BeOne Medicines Ltd. insiders filed 0 open-market purchases and 9 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesONC

Key figures

Market capADS ratio not in SEC data
–
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $48.5M in total
9
13F holdersQ2 2026
0
13F valueReported value at the end of Q2 2026
$0
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$5.34B
+40.2% year over year
Net income, FY2025
$286.9M
No comparable prior period
Free cash flow, FY2025
$941.7M
No comparable prior period
Revenue, Q3 FY2026
$1.89B
+33.8% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
163.5K
Shares sold short
Change
+72.7K
+80.1% vs. previous
Days to cover
2.47
At average daily volume

Superinvestors holding BEIGF, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BEIGF at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by BeOne Medicines Ltd. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 10, 2026 (view filing)4:59 PM ETNov 64 daysBall Titus B.Principal Accounting OfficerSSaleAmerican Depositary Shares−1.56K$405.57−$632.3K−100.0%0 after2 lots
Nov 9, 2026 (view filing)5:13 PM ETNov 54 daysLee Chan HenrySVP, General CounselSSaleAmerican Depositary Shares−1.11K$400.82−$446.9K−100.0%0 after2 lots10b5-1
Oct 29, 2026 (view filing)5:04 PM ETOct 272 daysWang XiaodongDirector, Other: Chair, Scientific Advisory BrdSSaleAmerican Depositary Shares−31.0K$362.97−$11.3M−100.0%0 after11 lots10b5-1
Oct 15, 2026 (view filing)5:08 PM ETOct 132 daysWang XiaodongDirector, Other: Chair, Scientific Advisory BrdSSaleAmerican Depositary Shares−31.0K$350.99−$10.9M−100.0%0 after5 lots10b5-1
Oct 2, 2026 (view filing)4:53 PM ETSep 302 daysLee Chan HenrySVP, General CounselSSaleAmerican Depositary Shares−1.11K$375.00−$418.1K−100.0%0 after10b5-1
Sep 30, 2026 (view filing)5:11 PM ETSep 282 daysWang XiaodongDirector, Other: Chair, Scientific Advisory BrdSSaleAmerican Depositary Shares−31.0K$364.79−$11.3M−100.0%0 after10 lots10b5-1
Sep 10, 2026 (view filing)4:49 PM ETSep 82 daysWang XiaodongDirector, Other: Chair, Scientific Advisory BrdSSaleAmerican Depositary Shares−38.3K$349.10−$13.4M−100.0%0 after8 lots10b5-1
Sep 3, 2026 (view filing)5:17 PM ETSep 12 daysBall Titus B.Principal Accounting OfficerSSaleAmerican Depositary Shares−132$355.86−$47.0K−100.0%0 after
Aug 27, 2026 (view filing)5:12 PM ETAug 252 daysWu XiaobinPresident and COOSSaleAmerican Depositary Shares−280$380.00−$106.4K−100.0%0 after10b5-1
Aug 13, 2026 (view filing)8:54 PM ETAug 112 daysLee Chan HenrySVP, General CounselSSaleAmerican Depositary Shares−2.67K$360.00−$959.8K−100.0%0 after10b5-1

Top 10 13F holders, Q2 2026

View all: Top 10 13F holders, Q2 2026

The largest institutional positions in BeOne Medicines Ltd. at the end of Q2 2026; share changes are against Q1 2026.

No institution reported holding BEIGF in 13F filings for Q2 2026.

2 members of Congress reported 3 trades in BeOne Medicines Ltd. since 2020. Newest filings:

  1. Daniel S. Goldman

    House · NY · Aug 13, 2023

    Sell$1K-$15K

  2. Daniel S. Goldman

    House · NY · Aug 13, 2023

    Sell$1K-$15K

  3. Greg Gianforte

    House · MT · Dec 2, 2020

    Buy$1K-$15K